RECRUITING

Effectiveness of Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep - Clinical Trial

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators propose to expand our previous work to test whether 10 repeated administrations of the cTBS procedure over a two-week period can lead to longer-term improvements in sleep, perhaps up to 3-months. For this 3-year study, 120 people with insomnia will be recruited to participate. There will be an initial screening, with the first consent form being for the screening questions, a psychological interview, and a one night at home sleep monitoring session with our equipment. If participants pass this first phase, they will reconsent for the main portion of the study. They will then undergo a physical examination, then a week-long at-home monitoring phase where they will wear a wristwatch sleep monitor as well as wear a portable brain wave monitor to bed each night to record sleep. Participants will continue to use this equipment throughout the treatment phase and for one week post treatment. After the first monitoring phase, each participant will be randomly assigned to one of four different conditions (i.e., 30 assigned to each group). Three of the conditions will involve cTBS focused on different brain locations (i.e., stimulation to the middle front, middle back, or side of the skull), while the fourth condition will provide inactive sham stimulation as a control. All participants will complete 10 treatment visits to the lab over two-to-three weeks, during which they will get a brief cTBS or sham stimulation each time. In addition, all participants will complete a brain scanning and cognitive testing session at the beginning and end of the two-to-three week treatment period. Participants will also complete 1-month and 3-month online follow-up assessments to examine long-term effects.

Official Title

Effectiveness of Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep - Clinical Trial

Quick Facts

Study Start:2025-04-28
Study Completion:2027-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06631209

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Healthy men and non-pregnant women 18-60 (inclusive) years of age free from contraindicated diseases, medications, devices, and conditions.
  2. * Must score in the moderate or higher range on the Insomnia Severity Index (ISI ≥ 15)
  3. * Must meet the criteria for DSM-5 insomnia disorder as determined by a clinical interview with a board-certified sleep medicine physician.
  4. * Sex ratio will be set to \~50% males; \~50% females
  5. * Ethnicity ratio will be set to \~29.5% who identify as a minority; \~70.5% who identify as white
  1. * Presence of any metal implant or medical device that may pose a safety risk for MRI or TMS (permanent hearing aids, cochlear implants, medication infusion devices, brain stimulation devices, permanent retainer, etc.)
  2. * Self-reported past or present medical diagnosis of sleep or breathing-related disorders such as sleep apnea other than insomnia (potential confounder);
  3. * Confounder of Obstructive Sleep Apnea as measured by WatchPAT device at home
  4. * Travel outside the time zone within the one week prior to the physical visit and at any point while active in the study (known to affect sleep);
  5. * Regular shiftwork within 6-months prior to enrollment in the study (known to affect sleep);
  6. * Self-reported past or present history of any seizures or seizure disorders or other contraindication to neurostimulation, for self or any first-degree relatives (safety concern);
  7. * Self-reported current use of certain prescription medications that can either influence seizure threshold, or neuroimaging findings (safety concern and potential confounder);
  8. * Self-reported caffeine use in excess of 300 mg (e.g., approximately 8 caffeinated sodas or approximately 3-4 12-oz cups of coffee) per day on average (known to affect sleep; potential confounder);
  9. * Self-reported or suspected substance abuse or dependence (safety concern; potential confounder);
  10. * (Females only) Positive urine pregnancy result (Urine HCG Test results) (safety concern);
  11. * Inability to read and sign the consent form (regulatory/ethical issue)
  12. * Self-reported history of repeated, recent, or severe fainting spell or syncope
  13. * Prior spinal cord surgeries or any spinal/ventricular derivations
  14. * Self-reported negative experience due to neurostimulation before
  15. * Deviation from self-reported normal bedtime sleep schedules (bedtime between 9:00 pm and 1:00 am

Contacts and Locations

Study Contact

William Killgore, Ph.D.
CONTACT
520-621-0605
killgore@psychiatry.arizona.edu

Study Locations (Sites)

SCAN Lab
Tucson, Arizona, 85724
United States

Collaborators and Investigators

Sponsor: University of Arizona

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-28
Study Completion Date2027-08

Study Record Updates

Study Start Date2025-04-28
Study Completion Date2027-08

Terms related to this study

Keywords Provided by Researchers

  • Sleep Quality
  • Transcranial Magnetic Stimulation

Additional Relevant MeSH Terms

  • Insomnia